J&J's ma­jor de­pres­sive dis­or­der drug hits end­points in Phase 3 tri­al

Last year
R&D

In­smed, Merus an­nounce pub­lic of­fer­ings; AI start­up rais­es $13M seed round

Last year
News Briefing

New York start­up rais­es $33M for fer­til­i­ty treat­ment based on George Church’s stem cell re­search

Last year
Financing
Cell/Gene Tx

Bris­tol My­ers pays $80M to li­cense an­oth­er Prothena neu­ro­science can­di­date

Last year
Deals

Ike­na On­col­o­gy weighs ‘strate­gic op­tions’ as it drops can­cer as­set, trims head­count to save cash

Last year
People
R&D

Arc­turus teas­es da­ta from small tri­al of in­hal­able cys­tic fi­bro­sis mR­NA ther­a­py, stock rock­ets 

Last year
R&D

Mer­ck re­turns to lu­cra­tive eye dis­ease mar­ket in up to $3B deal for Eye­Bio

Last year
Startups
Deals

As­traZeneca re­veals ear­ly da­ta for oral PC­SK9, touts PK edge over Mer­ck’s drug

Last year
R&D

NIH-fund­ed tri­als of­ten miss di­ver­si­ty tar­gets, small study shows

Last year
Pharma
FDA+

FDA de­tails new 'plat­form tech­nol­o­gy' process that could ac­cel­er­ate cell and gene ther­a­py ap­provals

Last year
Cell/Gene Tx
FDA+

NIH of­fi­cials used per­son­al emails, tweaked words to skirt FOIA search­es dur­ing pan­dem­ic, law­mak­ers find

Last year
Pharma
FDA+

GLP-1 pre­scrip­tions reach all-time high as Lil­ly and No­vo scram­ble to keep pace with de­mand

Last year
Pharma
Manufacturing

Cana­di­an biotech VC Am­pli­tude rais­es $192M sec­ond fund

Last year
Financing
Startups

Louisiana gov­er­nor signs law lim­it­ing abil­i­ty of doc­tors to pre­scribe abor­tion med­ica­tions

Last year
Pharma
Law

Joe Panet­ta to step down as Bio­com Cal­i­for­nia CEO

Last year
People

Sec­ond en­gi­neered B cell ther­a­py en­ters the clin­ic, promis­ing to do in he­mo­phil­ia B what gene ther­a­pies can't

Last year
R&D
Cell/Gene Tx

In­smed stock sky­rock­ets on Phase 3 lung dis­ease da­ta

Last year
R&D

Agios sells rights to glioma drug to Roy­al­ty Phar­ma; Car­go’s $110M place­ment

Last year
News Briefing

J&J makes an­oth­er I&I ac­qui­si­tion with $1.25B deal for Num­ab's Yel­low Jer­sey

Last year
Deals
Pharma

NewAms­ter­dam says for­mer Am­gen car­dio drug re­duces heart dis­ease risk fac­tor

Last year
R&D

Take­da to lay off 640 work­ers in Mass­a­chu­setts as part of mul­ti­year over­haul

Last year
People

Duchenne mus­cu­lar dy­s­tro­phy drug flunks Phase 3 con­fir­ma­to­ry tri­al

Last year
R&D

Cor­rect­ed: As­traZeneca, Dai­ichi Sankyo’s TROP2 ADC boosts sur­vival in Phase 3 lung can­cer sub­group

Last year
R&D

Gilead forms pact with Car­tog­ra­phy to map new tar­gets for can­cer drugs

Last year
Startups
Deals
First page Previous page 151152153154155156157 Next page Last page
A service from the Financial Times